A Phase 2 interventional study of fluorouracil (5FU) and leucovorin in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 28 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-15.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 159 studies testing fluorouracil in Colorectal Neoplasms — 15 open to participants now, 19 under way, 4 of them phase 3. Fluorouracil · Colorectal Neoplasms.
Among the 159 studies testing fluorouracil in Colorectal Neoplasms, this one is the 60th largest by enrollment of the 132 interventional ones that give a count, is one of 5 that started in 2009, is one of 79 in phase 2, and was the 103rd registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →15 of the 159 studies testing fluorouracil in Colorectal Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 18–75
West China Hospital · Sites in China
Ages 18–85
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
159 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 87 · Phase 3 41 · Phase 4 5
First in 1977; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is close to the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 66 across the 132 interventional studies. Of the 110 that completed or were terminated, 18 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 159 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 7 under way, none of them phase 3. Of 99 finished, 52 (53%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 43rd largest by enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2009, is one of 32 in phase 2, and was the 38th registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
5 of the studies testing fluorouracil in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00335816Memorial Sloan Kettering Cancer CenterRadiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer | 2026-12 |
| NCT06654037National Cancer Institute (NCI)Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer | 2027-04-01 |
| NCT07158164Rutgers, The State University of New JerseyDPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment | 2027-07-07 |
| NCT07123441Sanjun CaiA Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer | 2027-09-01 |
| NCT06269978Arjun MittraIntraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 159 studies testing fluorouracil in Colorectal Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This open-label single arm study will evaluate the efficacy and safety of Avastin added to XELOX or FOLFOX in patients with metastatic colorectal cancer and disease progression on 1st line therapy with FOLFIRI plus Avastin. Patients will receive either Avastin (7.5mg/kg iv infusion every 3 weeks) and standard XELOX (Xeloda [capecitabine] plus oxaliplatin) chemotherapy or Avastin (5 mg/kg iv infusion every 2 weeks) and standard FOLFOX (5-FU and leucovorin plus oxaliplatin) chemotherapy. The anticipated time on study treatment is until disease progression, and the target sample size is 100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: fluorouracil (5FU) · Drug: leucovorin · Drug: bevacizumab [Avastin] · Drug: capecitabine [Xeloda] · Drug: oxaliplatin
standard FOLFOX regimen
standard FOLFOX regimen
7.5 mg/kg iv infusion every 3 weeks OR 5 mg/kg iv infusion every 2 weeks
standard XELOX regimen
standard XELOX or FOLFOX regimen
Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression
PFS from the start of treatment beyond progression was defined as the interval between the start of beyond-progression therapy and the date at which disease progression was documented. Progression of disease was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 and abdominal/pelvic computerized tomography (CT) or magnetic resonance imaging (MRI) scanning as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The same method of assessment and the same technique were to be used to evaluate each lesion throughout the entire study. If more than one method was used, data from the most accurate method according to RECIST were recorded. Median PFS was estimated using the Kaplan-Meier method.
Time frame: Baseline, every 9 weeks until disease progression, at end of treatment or withdrawal, for up to 24 months
PFS From the Start of First-Line Therapy
PFS from the start of first-line therapy was defined as the interval between the start of first-line therapy and the date at which second disease progression (after the start of beyond progression therapy) was documented. Progression of disease was evaluated using RECIST version 1.1 and abdominal/pelvic CT or MRI scanning. The same method of assessment and the same technique were to be used to evaluate each lesion throughout the entire study. If more than one method was used, data from the most accurate method according to RECIST were recorded. Median PFS was estimated using the Kaplan-Meier method.
Time frame: Baseline, every 9 weeks until disease progression, at end of treatment or withdrawal, for up to 24 months
Percentage of Participants With an Overall Response of Complete Response (CR) or Partial Response (PR)
Percentage of participants with an overall response of CR or PR according to RECIST criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\]10 millimeters \[mm\]). No new lesions. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
Time frame: Baseline, every 9 weeks until disease progression, at end of treatment or withdrawal, for up to 24 months
Geometric Mean Values of Pro-Angiogenic Cytokine Concentrations at Baseline and Prior to Progression
Pro-angiogenic cytokine concentrations of placental growth factor (PlGF), basic fibroblast growth factor (bFGF), and hepatocyte growth factor (HGF) in participant sera were measured and reported in units of picograms/milliliter (pg/mL). The geometric mean was calculated as exp10 (mean of log10 transformed concentration) and the standard deviation (SD) is SD of log10 transformed concentration.
Time frame: Baseline, every 9 weeks until disease progression, at final visit or at withdrawal, for up to 24 months
| Milestone | Bevacizumab + Oxaliplatin + Capecitabine | Bevacizumab + 5-fluorouracil/Oxaliplatin/Leucovorin (FOLFOX) |
|---|---|---|
| Started | 25 | 50 |
| Completed | 20 | 40 |
| Not completed | 5 | 10 |
| Withdrew: Premature withdrawal | 1 | 3 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Death | 0 | 3 |
| Withdrew: Unacceptable toxicity | 1 | 2 |
| Withdrew: Other | 2 | 2 |
PFS from the start of treatment beyond progression was defined as the interval between the start of beyond-progression therapy and the date at which disease progression was documented. Progression of disease was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 and abdominal/pelvic computerized tomography (CT) or magnetic resonance imaging (MRI) scanning as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The same method of assessment and the same technique were to be used to evaluate each lesion throughout the entire study. If more than one method was used, data from the most accurate method according to RECIST were recorded. Median PFS was estimated using the Kaplan-Meier method.
| months | Bevacizumab + Oxaliplatin + Capecitabine | Bevacizumab + FOLFOX |
|---|---|---|
| Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression | 6.3 (4.1 to 7.6) | 5.1 (3.8 to 6.0) |
PFS from the start of first-line therapy was defined as the interval between the start of first-line therapy and the date at which second disease progression (after the start of beyond progression therapy) was documented. Progression of disease was evaluated using RECIST version 1.1 and abdominal/pelvic CT or MRI scanning. The same method of assessment and the same technique were to be used to evaluate each lesion throughout the entire study. If more than one method was used, data from the most accurate method according to RECIST were recorded. Median PFS was estimated using the Kaplan-Meier method.
| months | Bevacizumab + Oxaliplatin + Capecitabine | Bevacizumab + FOLFOX |
|---|---|---|
| PFS From the Start of First-Line Therapy | 17.8 (14.1 to 19.4) | 18.0 (15.0 to 19.9) |
Percentage of participants with an overall response of CR or PR according to RECIST criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\]10 millimeters \[mm\]). No new lesions. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
| percentage of participants | Bevacizumab + Oxaliplatin + Capecitabine | Bevacizumab + FOLFOX |
|---|---|---|
| Percentage of Participants With an Overall Response of Complete Response (CR) or Partial Response (PR) | 27.3 | 6.4 |
Pro-angiogenic cytokine concentrations of placental growth factor (PlGF), basic fibroblast growth factor (bFGF), and hepatocyte growth factor (HGF) in participant sera were measured and reported in units of picograms/milliliter (pg/mL). The geometric mean was calculated as exp10 (mean of log10 transformed concentration) and the standard deviation (SD) is SD of log10 transformed concentration.
| pg/mL | Bevacizumab + Oxaliplatin + Capecitabine | Bevacizumab + FOLFOX |
|---|---|---|
| Baseline bFGF (n=13,23) | 6.8 ± 0.7 | 6.1 ± 0.6 |
| bFGF, Prior to progression levels (n=12,18) | 3.6 ± 0.9 | 4.2 ± 0.7 |
| Baseline HGF (n=13,23) | 133.0 ± 0.3 | 186.0 ± 0.4 |
| HGF, Prior to progression levels (n=12,18) | 187.3 ± 0.4 | 230.3 ± 0.4 |
| Baseline PIGF (n=13,23) | 29.8 ± 0.1 | 26.3 ± 0.2 |
| PIGF, Prior to progression levels (n=12,18) | 34.7 ± 0.1 | 37.1 ± 0.2 |
Collected over Adverse events (AEs) were reported from Day 1 until 28 days after last dose of study medication for up to 24 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab + Oxaliplatin + Capecitabine | — | 12/25 (48%) | 24/25 (96%) |
| Bevacizumab + FOLFOX | — | 18/50 (36%) | 49/50 (98%) |
| Event | Bevacizumab + Oxaliplatin + Capecitabine | Bevacizumab + FOLFOX |
|---|---|---|
| Drug toxicityInjury, poisoning and procedural complications | 2/25 | 0/50 |
| DehydrationMetabolism and nutrition disorders | 2/25 | 1/50 |
| General physical health deteriorationGeneral disorders | 0/25 | 3/50 |
| Abdominal painGastrointestinal disorders | 1/25 | 1/50 |
| Abdominal pain upperGastrointestinal disorders | 1/25 | 1/50 |
| Anal fistulaGastrointestinal disorders | 1/25 | 0/50 |
| DiarrhoeaGastrointestinal disorders | 1/25 | 2/50 |
| EnteritisGastrointestinal disorders | 1/25 | 0/50 |
| VomitingGastrointestinal disorders | 1/25 | 1/50 |
| AstheniaGeneral disorders | 1/25 | 0/50 |
| Event | Bevacizumab + Oxaliplatin + Capecitabine | Bevacizumab + FOLFOX |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 14/25 | 21/50 |
| FatigueGeneral disorders | 9/25 | 22/50 |
| NauseaGastrointestinal disorders | 10/25 | 16/50 |
| Abdominal painGastrointestinal disorders | 9/25 | 13/50 |
| Decreased appetiteMetabolism and nutrition disorders | 9/25 | 12/50 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 8/25 | 2/50 |
| Neuropathy peripheralNervous system disorders | 7/25 | 9/50 |
| HypertensionVascular disorders | 3/25 | 13/50 |
| VomitingGastrointestinal disorders | 6/25 | 5/50 |
| ParaesthesiaNervous system disorders | 6/25 | 10/50 |
Intent-to-treat (ITT) population: all enrolled participants who received at least 1 dose of the investigational and non-investigational products.
| Age, Continuous(years) | Bevacizumab + Oxaliplatin + Capecitabine | Bevacizumab + FOLFOX | Total |
|---|---|---|---|
| Mean | 59.6 ± 8.9 | 64.9 ± 8.7 | 63.1 ± 9.0 |
| Sex: Female, Male(Participants) | Bevacizumab + Oxaliplatin + Capecitabine | Bevacizumab + FOLFOX | Total |
|---|---|---|---|
| Female | 8 | 21 | 29 |
| Male | 17 | 29 | 46 |
The record gives a start of Jul 2009, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluorouracil · Leucovorin · Bevacizumab · Capecitabine · Oxaliplatin